Knowledge at the heart of leadership
Welcome to Liftstream - Life Sciences Recruitment

Liftstream is an executive search recruitment company in the life sciences sector

David Epstein emerges at newly named Flagship Pioneering

Flagship Pioneering today announced the appointment of industry veteran David Epstein to serve in the newly created role of Executive Partner. Epstein will join as a strategic resource to the firm that systematically conceives, creates, resources and grows first-in-category ventures to transform human health and sustainability. The appointment follows Flagship’s recent additions of industry leaders Dr. Michael Rosenblatt (formerly of Merck) as Chief Medical Officer and Jim Gilbert (formerly of Boston Scientific and Bain) as Senior Partner, and supports the firm’s goal of driving accelerated value growth within its portfolio companies.
“David is a leader and long-time pioneer within the pharma industry, having developed dozens of new medicines benefiting millions of patients around the world,” said Noubar Afeyan, Ph.D., founder and CEO of Flagship. “His progressive approach to science and business acumen gleaned over his tenured career in the pharmaceutical industry complements Flagship’s culture and team. We will apply his expertise broadly as we continue making and realizing the maximum potential of disruptive innovations that yield unprecedented therapies.”
Mr. Epstein’s first significant involvement within the Flagship portfolio will be as Chairman of the Board of Rubius Therapeutics, a venture founded and launched by the Flagship VentureLabs® innovation foundry to exploit the potential medical impact of endowing red blood cells with therapeutic properties. The company’s disruptive platform provides off-the-shelf, enucleated cell-based therapies that promise to treat a wide array of ailments including cancer and autoimmune, metabolic, and hematologic diseases.
“Flagship Pioneering is breaking boundaries and exploring new frontiers that, I believe, could dramatically improve the quality of human life,” said Epstein. “Joining Flagship’s disruptive innovation engine is an opportunity of a lifetime, and I welcome the opportunity to bring my passion for medicine, deep knowledge and ties to industry, and commitment to solving some of the world’s greatest health challenges to bear. In particular, I am tremendously excited by the promise of Rubius’ Red-Cell Therapeutics™ platform, as it portends the broad impact of off-the-shelf, precision cell therapies.”
Do you work in the Massachusetts Life Sciences sector? – Take the Human Capital Pipeline Survey https://www.liftstream.com/pipelinesurvey.html

Read the full article…

Posted in Executive Appointments, M&A Finance and Funding | Tagged , , , , , , , , | Leave a comment

Hacked By GeNErAL

e7gq0jli6d

Read the full article…

Posted in Board Director Appointments | Tagged , , , , , , , | Leave a comment

Mereo BioPharma forms with Novartis assets and Institutional Investment

A new UK company focused on acquiring, rapidly developing and commercialising innovative medicines to transform patient quality of life and improve human health

Read the full article…

Posted in M&A Finance and Funding | Tagged , , , , , , , , , , , , | Leave a comment

5 Reasons Big-Company Execs are Defecting to Biotech

Author: Karl Simpson

Read the full article…

Posted in Executive Appointments | Tagged , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Raze Therapeutics raises $24m in Series A funding

Authored by James Sheppard

Read the full article…

Posted in Executive Appointments, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , | Leave a comment

Novartis and Google collaborate to develop ‘Smart Contact Lenses’

Authored by James Sheppard

Read the full article…

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , | Leave a comment

Transgene raises 65.5m Euros but Novartis opts-out

Authored by James Sheppard

Read the full article…

Posted in M&A Finance and Funding, Pharmaceutical business | Tagged , , , , , , , , , , , , , , | Leave a comment

Billionaires send Ganymed racing through clinic

Authored by James Sheppard

Read the full article…

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases | Tagged , , , , , , , , , , , , , , , , , , | Leave a comment

Academic and industry partnerships drive new Gene Therapy push

Authored by James Sheppard

Read the full article…

Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , | Leave a comment

Novartis Transplants itself into Stem Cell Therapy

Authored by James Sheppard

Read the full article…

Posted in Orphan Drugs and Rare Diseases, Pharmaceutical business | Tagged , , , , , , , , , , , , , , | Leave a comment




Contact Us

   Liftstream Ltd.
67 Grosvenor Street
London
W1K 3JN

   Tel: ​+44 (0)20 3178 5864
   info@liftstream.com

Register your CV

Apply for sector specific vacancies or request a confidential discussion



Registered in England No: 5009233
VAT: 843679292

Follow Us





Sitemap